<DOC>
	<DOCNO>NCT00728390</DOCNO>
	<brief_summary>This study explore combination oral drug PF-00299804 intravenous CP-751,871 patient advance solid tumor . Each drug give separately patient prior study , study establish safety efficacy combination .</brief_summary>
	<brief_title>A Safety And Efficacy Study Of The Combination Of Oral PF-00299804 And Intravenous CP-751,871 Given Every 3 Weeks</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>Histologically document advanced cancer , Eastern Cooperative Oncology Group ( ECOG ) 01 ; Platelets &gt; 100,000 , ANC &gt; 1500 ; Ccr &gt; 60 serum creat . &lt; 1.5 Nonsmall cell cancer cohort : Eastern Cooperative Oncology Group ( ECOG ) 02 , prior platin , &lt; 4 prior chemotherapy regimen HgA1C &lt; 5.7 % Active Central Nervous System ( CNS ) metastases ; prior IGF1R target therapy Any history unstable angina , myocardial infarction symptomatic congestive heart failure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>advanced cancer refractory advance non-small cell lung cancer</keyword>
</DOC>